Forte Bio­sciences shares col­lapse af­ter lead bac­te­ria drug flops key eczema study

With a unique strat­e­gy to take on eczema with a com­bi­na­tion of “ther­a­peu­tic” bac­te­ria strains, Forte Bio­sciences has now fold­ed like a house of cards af­ter its lead drug flopped a key study.

Forte’s atopic der­mati­tis can­di­date FB-401, a com­bi­na­tion of three strains of com­men­sal gram-neg­a­tive bac­te­ria, failed its pri­ma­ry end­point re­duc­ing the sever­i­ty of symp­toms by 50% or more against place­bo, the com­pa­ny said Thurs­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.